SSI Diagnostica (Adelis portfolio) Acquires CTK Biotech

August 26, 2020

Adelis Equity Partners portfolio company SSI Diagnostica has acquired US-based CTK Biotech to create a global rapid diagnostics leader focused on respiratory and tropical disease tests. The deal combines SSI Diagnostica's Nordic IVD capabilities and distribution with CTK's product development and manufacturing (headquartered in San Diego with a manufacturing plant in Beijing), and triggers a CEO change and several board appointments.

Buyers
SSI Diagnostica, Adelis Equity Partners
Targets
CTK Biotech
Platforms
SSI Diagnostica
Industry
Medical Devices
Location
California, United States
Transaction Type
Addon

Explore More

Related articles

Build a buyer list for your deal

Find active buyers from recent acquisition patterns and move straight into outreach.

Find buyers like these →